Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing coronary artery bypass graft (CABG) surgery. It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.



Investigated for use/treatment in cardiac reperfusion injury, cardiovascular disorders, and coronary artery disease.


Acadesine has been shown to induce cell death apoptosis selectively in B-cells taken from healthy subjects and patients with B-CLL, with little effect on T-cells. As T-cells have an important role in fighting infection, it is anticipated that patients treated with acadesine will have a reduced risk... Read more

Mechanism of action

The mechanism by which acadesine selectively kills B-cells is not yet fully elucidated. The action of acadesine does not require the tumour suppressor protein p53 like other treatments. This is important, as p53 is often missing or defective in cancerous B-cells. Studies have shown acadesine activat... Read more


Information currently not available.

Protein binding

Negligible (approximately 1%)

Volume of distribution

Information currently not available.


Information currently not available.

Half life

1 week

Route of elimination

Information currently not available.


Information currently not available.

Adverse Effects


Information currently not available.

Food Interactions

    Information currently not available.


Type in a drug name to check for interaction with Acadesine
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
4 References
  1. 1 . Dixon R, Fujitaki J, Sandoval T, Kisicki J: Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent. J Clin Pharmacol. 1993 Oct;33(10):955-8.PubMed: 8227467
  2. 2 . Menasche P, Jamieson WR, Flameng W, Davies MK: Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational Acadesine Study Group. J Thorac Cardiovasc Surg. 1995 Oct;110(4 Pt 1):1096-106.PubMed: 7475138
  3. 3 . Nawarskas JJ: Acadesine: a unique cardioprotective agent for myocardial ischemia. Heart Dis. 1999 Sep-Oct;1(4):255-60.PubMed: 11720632
  4. 4 . Campas C, Lopez JM, Santidrian AF, Barragan M, Bellosillo B, Colomer D, Gil J: Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood. 2003 May 1;101(9):3674-80. Epub 2003 Jan 9.PubMed: 12522004